Mer­ck ax­es two of nine AD­Cs in pact with Kelun-Biotech

Last year
Deals
China

Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

Last year
R&D

Ear­ly da­ta on Dai­ichi Sankyo’s Mer­ck-part­nered ADC; As­traZeneca’s Da­to-Dxd com­bo; more from Seagen: #ES­MO23 ...

Last year
R&D
Pharma

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Last year
Deals
Pharma

Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

Last year
R&D
Pharma

Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

Last year
R&D
Pharma

CAR­GO Ther­a­peu­tics heads to Nas­daq in first CAR-T cell ther­a­py IPO pitch of 2023

Last year
Financing
Startups

Ic­ahn law­suit calls for mil­lions in dam­ages, re­moval of Il­lu­mi­na board mem­bers

Last year
Law

Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in ...

Last year
Weekly

Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Last year
R&D
Pharma

A first for the Eu­ro­pean Com­mis­sion: Five phar­ma com­pa­nies fined $14M for API price fix­ing

Last year
Pharma

Pfiz­er wins first US ap­proval for pen­tava­lent meningo­coc­cal vac­cine 

Last year
Pharma
FDA+

House Re­pub­li­cans threat­en sub­poe­na over de­tails of NIH mpox re­search

Last year
FDA+

RWD and RWE are not the same: FDA lead­ers dis­pel com­mon mis­con­cep­tions in new pa­per

Last year
Pharma
FDA+

Nec­tar Life­sciences hit with un­ti­tled let­ter over re­peat GMP is­sues at an­timi­cro­bial site

Last year
FDA+
Manufacturing

Eli Lil­ly cracks down on im­porters and dis­trib­u­tors of com­pound­ed Moun­jaro

Last year
Pharma

Every­one wants an ADC: GSK pays $85M up­front for ex-Chi­na rights to Han­soh Phar­ma's an­ti­body-drug con­ju­gate

Last year
Deals

French biotech Abi­vax makes Nas­daq de­but, aim­ing to raise $236M to get PhI­II da­ta in IBD

Last year
Financing

Bio­gen CEO Chris Viehbach­er: Im­munol­o­gy is a nat­ur­al fit at biotech, calls for 'rein­ven­tion'

Last year
People

Keytru­da's cer­vi­cal can­cer da­ta; Ar­cutis’ of­fer­ing; Alaya.bio an­nounces a CAR-T deal

Last year
News Briefing

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Last year
R&D

J&J un­veils PhI­Ia da­ta of oral an­tivi­ral for dengue fever pre­ven­tion

Last year
R&D

#ES­MO23 dis­patch: What to know about the HER3 ADC that got Mer­ck to pay $2B cash

Last year
Deals

Co-found­ed by David Bak­er, Vilya rings in a per­ma­nent CEO; Al­lo­gene names Er­ic Schmidt's CFO suc­ces­sor

Last year
Peer Review
First page Previous page 266267268269270271272 Next page Last page
A service from the Financial Times